3-(4-Chlorophenyl)-4-cyano-5-cyclohexylsulfanylthiophene-2-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 3-(4-Chlorophenyl)-4-cyano-5-cyclohexylsulfanylthiophene-2-carboxylic acid
• 化学式: C₁₈H₁₆ClNO₂S₂
• 分子量: 377.9
• InChiKey: WOWRURLWMICNPY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  115
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Thiophene derivatives for up-regulating HLA-DM activity
  申请人：Yeh Li-An

  公开号：US20100143404A1

  公开（公告）日：2010-06-10

  Compounds of formula (I), compositions, methods and kits are provided. The compounds and compositions may be particularly useful for modulating immunological responses. Formula (I) wherein, R 1 is alkyl, aryl, or heterocyclyl; R 2 is H, alkyl, aryl, heterocyclyl, OR 3 or N(R 3 ) 2 , R 3 is H, alkyl, aryl, or heterocyclyl; R 4 is H, CN, halogen, CF 3 , CO 2 R 3 , or C(O)N(R 3 ) 2 ; X is S, SO 2 , O, or NR 3 ; and Y is S, O, or NR 3 .
• INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT NEUROINFLAMMATORY DISORDERS
  申请人：TABACZYNSKI David A.

  公开号：US20160303146A1

  公开（公告）日：2016-10-20

  This invention provides methods and pharmaceutical compositions that can treat neuroinflammatory disease by reducing the production of pyrophosphate intermediates produced during the biosynthesis of isoprenoids. The pyrophosphate compounds being inhibited are normally produced through the mevalonate and non-mevalonate pathways of the host vertebrate organisms and their symbiotic and pathogenic microorganisms. The methods involve administering to a patient an inhibitor of the mevalonate-dependent pathway, an inhibitor of the non-mevalonate pathway, or combination of such inhibitors.
• INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT AUTOIMMUNE DISORDERS
  申请人：TABACZYNSKI David A.

  公开号：US20160375041A1

  公开（公告）日：2016-12-29

  The invention provides methods and pharmaceutical compositions that can treat autoimmune disease by reducing the production of pyrophosphate intermediates produced during the biosynthesis of isoprenoids. The pyrophosphate compounds being inhibited are normally produced through the mevalonate and non-mevalonate pathways of the host vertebrate organisms and their symbiotic and pathogenic microorganisms. The methods involve administering to a patient an inhibitor of the mevalonate-dependent pathway, an inhibitor of the non-mevalonate pathway, or combination of such inhibitors.
• US8119684B2
  申请人：——

  公开号：US8119684B2

  公开（公告）日：2012-02-21